Skip to main content
Report File
Date Issued
Submitting OIG
Department of Health & Human Services OIG
Other Participating OIGs
Department of Health & Human Services OIG
Agencies Reviewed/Investigated
Department of Health & Human Services
Components
Food and Drug Administration
Report Number
OEI-01-17-00090
Report Description

To provide FDA with insights to improve its oversight of compounders and enhance patient safety, OIG determined the extent to which hospitals purchase non-patient-specific compounded drugs from outsourcing facilities.

Report Type
Inspection / Evaluation
Agency Wide
Yes
Additional Details
https://oig.hhs.gov/oei/reports/OEI-01-17-00090.asp

Open Recommendations

This report has 2 open recommendations.
Recommendation Number Significant Recommendation Recommended Questioned Costs Recommended Funds for Better Use Additional Details
5855 No $0 $0

FDA should further communicate to hospitals the importance of obtaining NPS compounded drugs from outsourcing facilities

5856 No $0 $0

FDA should take appropriate followup action with the unregistered compounding facilities on the list that we provided

Department of Health & Human Services OIG

United States